Windlas Biotech Limited
Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics.
What Windlas files
- Investor Meet58
- Others37
- Updates17
- Board Meeting10
- PPTs8
- Important6
Windlas Biotech officials are scheduled to meet with ICICI Direct, Bajaj Broking, a group of investors, and Haitong Securities on Monday, September 7, 2026. These virtual meetings will include one-on-one and group interactions, with discussions referring to publicly available documents and no unpublished price sensitive information to be shared.
Windlas Biotech reported Q1 FY27 revenue of INR 248 Cr, up 18% YoY, marking its 14th consecutive quarter of record revenue. EBITDA (ex-ESOP) grew 26% to INR 34 Cr, with PAT (ex-ESOP) up 37% to INR 25 Cr. The CDMO vertical revenue surged 29% to INR 207 Cr. Exports also...
Windlas Biotech has uploaded the audio recording of its Investors/Analyst conference call. The call discussed the unaudited standalone financial results for the quarter ended June 30, 2026. The recording is available on the company's website. A transcript will be shared and uploaded online soon.
Windlas Biotech reported record revenue of ₹248 Cr (up 18% YoY). Adjusted EBITDA grew 26% to ₹34 Cr, PAT 37% to ₹25 Cr. Company completed a ₹47 Cr share buyback and paid ₹13 Cr dividend for FY26. Plant-6 commercialization is on track.
Windlas Biotech kicked off FY27 with strong Q1 performance, achieving its 14th consecutive quarter of record revenue at **Rs 248 Cr, up 18% YoY**. Adjusted EBITDA grew **26% to Rs 34 Cr**, and adjusted PAT jumped **37% to Rs 25 Cr**, excluding non-cash ESOP expenses. EPS improved to **Rs 8.46**....